Skip to main content

Table 1 Inhibition of M. pneumoniae growth by nucleoside and nucleobase analogs*

From: Inhibition of Mycoplasma pneumoniae growth by FDA-approved anticancer and antiviral nucleoside and nucleobase analogs

Compounds

Wild type MIC (μg ml-1)

thyA mutant MIC (μg ml-1)

Ribavirin

62.5

> 500

Pentoxifylline

62.5

> 500

Gancyclovir

7.8

> 500

Zidovudine

7.8

7.8

Gemcitabine (dFdC)

2.4

2.4

Stavudine

7.8

17.8

Acyclovir

15.6

15.6

Pyrimethamine

> 500

> 500

Fludarabine phosphate

> 500

> 500

Lamivudine

> 500

> 500

Mycophenolate mofetil

250

250

Trifluorothymidine (TFT)

1.8

1.8

Adefovir depivoxil

> 500

> 500

5-azacytidine

> 500

> 500

Azathioprine

> 500

> 500

Arabinosyl adenine

> 500

> 500

Zalcitabine

> 500

> 500

5-iododeoxyuridine

15.6

> 500

5-fluorodeoxyuridine (5FdU)

7.8

15.6

Cidofovir

31.2

31.2

Caffeine

> 500

> 500

7-(2,3-dihydroxypropyl)theophylline

> 500

> 500

Theophylline

> 500

> 500

6-thioguanine (6-TG)

0.2

0.2

Allopurinol

> 500

> 500

6-mercaptopurine (6-MP)

> 500

> 500

5-fluorouracil

31.2

31.2

5-fluorocytosine

31.2

31.2

Valacyclovir

> 500

> 500

Dipyridamole

1.9

1.9

  1. *MIC = minimal concentrations of the compound that produced 90% inhibition.